Vaccine Breaking News

Vaccine breaking news brought to you by Precision Vaccinations.

Jun 24, 2022 • 1:38 am CDT
NYC Health

The Health Department of New York City confirmed it had opened a free vaccination clinic for anyone exposed to the monkeypox virus. As of June 23, 2022, NYC Health 30 people in New York City had tested positive for orthopoxvirus, which indicates a monkeypox infection.

In NYC, eligible people can get the two-dose Jynneos vaccine at the Chelsea Sexual Health Clinic, 303 Ninth Avenue in Manhattan.

Jynneos is indicated for preventing smallpox and monkeypox disease in adults at high risk for smallpox or monkeypox infection.

Vaccination of monkeypox patients' close contacts (PEP) is based on a 'risk exposure assessment.'

Unfortunately, all Jynneos vaccination appointment slots have already been filled through June 27, 2022, says NYC Health.

'We are requesting additional vaccine supply from the U.S. CDC to meet the high demand.'

Manhattan's Mark Levine recently Tweeted: 'NYC has only been given about 1,000 doses of the monkeypox vaccine.'

'This is far, far too little. And now people are literally been turned away.'

In the USA, the CDC ships Jynneos vaccines to local health departments within a few days of a request.

As of June 14, 2022, the U.S. stockpile held about 36,000 vaccine courses in its immediate inventory.

According to Brett W. Petersen, M.D., MPH Captain, U.S. Public Health Service, presentation to the CDC's Advisory Committee on Immunization Practices on June 23, 2022, the Jynneos vaccine is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus, known internationally as IMVAMUNE, or IMVANEX.

Furthermore, the CDC is developing an Expanded Access Investigational New Drug Protocol to allow the use of JYNNEOS for monkeypox in pediatric populations.

From a national perspective, the CDC reported on June 23, 2022, that there have been about (173) confirmed monkeypox patients in over twenty states.

California has reported the most monkeypox cases (48) since early May 2022.

Globally, data sources indicate about 3,635 potential monkeypox cases reported.

The leading cities reporting monkeypox cases are London, Berlin, and Madrid.

Additional monkeypox vaccine and outbreak news are published daily before 5 pm CT.

Note: This information was manually curated for mobile readers.

Jun 23, 2022 • 4:16 pm CDT
by Alisa Dyson

New Jersey-based Seqirus announced yesterday that the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) had included FLUAD® QUADRIVALENT as a preferentially recommended seasonal influenza vaccine for adults 65 years of age and older.

The preferential recommendation for FLUAD QUADRIVALENT for seniors is based on the clinical benefits compared to standard egg-based influenza vaccines, as demonstrated within the total body of evidence.

'Prior to this announcement, seasonal flu vaccine guidelines for individuals 65 and older had not been updated since 2010.'

"It is critical that we do everything we can to protect vulnerable populations like older adults against influenza," commented Gregg Sylvester, MD, Chief Health Officer, Seqirus, in a press release on June 22, 2022.

"Today's recommendation is evidence of the ACIP's commitment to providing clear, evidence-backed guidance to protect public health."

"We are proud to offer one of the enhanced flu vaccines that were preferentially recommended by the ACIP for adults 65 years and above in the USA."

FLUAD QUADRIVALENT is created explicitly for seniors using Seqirus' MF59® adjuvant, designed to help strengthen, broaden and lengthen the immune response to influenza vaccination.

Immunosenescence, the age-associated decline of the immune system, may result in a reduced immune response to antigens in the vaccine.

Since it takes about two weeks after vaccination for antibodies to develop in the body that helps protect against influenza virus infection, it is recommended that people get vaccinated before influenza begins spreading in their community.

The CDC recommends that people get vaccinated by the end of October each year.

FLUAD is proven to be safe and effective and has an extensive clinical legacy, with more than 225 million doses distributed and licensure in over 30 countries since 1997.

Note: According to the ACIP, if one preferentially recommended influenza vaccine is unavailable for adults 65 years and older, then any other age-appropriate influenza vaccine should be used. This information was manually curated for mobile readers.

Jun 23, 2022 • 10:22 am CDT
by Dimitris Vetsikas

France-based Valneva SE announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended marketing authorization for Valneva's inactivated whole-virus COVID-19 vaccine, VLA2001, for use as primary vaccination in people from 18 to 50 years of age.

The CHMP concluded by consensus after a thorough evaluation that "the data on the vaccine were robust and met the EU criteria for efficacy, safety, and quality."

The European Commission (EC) will review the CHMP recommendation, and a decision on the marketing authorization is expected shortly.

If granted, this will be the first COVID-19 vaccine to receive standard marketing authorization in Europe, which would be valid in all European Union Member States and Iceland, Liechtenstein, and Norway.

Thomas Lingelbach, CEO of Valneva, commented in a press release issued on June 23, 2022, "We are pleased that the CHMP has recommended VLA2001, the only inactivated COVID-19 vaccine candidate in Europe, for full marketing authorization and are now looking forward to receiving marketing authorization from the EC."

"We hope the EC and its member states will recognize the potential advantages of an inactivated vaccine ..."

"Our aim is to further support public health in Europe by providing a new option for the 15% of Europeans over 18 who are not yet vaccinated."

The EMA's CHMP opinion follows conditional marketing authorization in the United Kingdom, granted in April 2022, emergency use authorization granted in the United Arab Emirates in May 2022, and Bahrain in March 2022.

VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.

It is intended for active immunization of at-risk populations to prevent carriage and symptomatic infection with COVID-19 during the pandemic and for routine vaccination, including addressing new variants.

VLA2001 may also be suited for boosting, as repeat booster vaccinations have been shown to work well with the whole virus inactivated vaccines.

Note: This announcement was manually curated for mobile readership.

Jun 22, 2022 • 2:02 pm CDT
by Jane b13

New Jersey-based Merck announced today that the U.S. Food and Drug Administration (FDA) had approved an expanded indication for its VAXNEUVANCE™ Pneumococcal 15-valent Conjugate Vaccine to include children six weeks through 17 years of age.

VAXNEUVANCE is now indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals six weeks of age and older.

Today's approval follows the FDA's Priority Review of Merck's supplemental application.

"Despite decreases in incidence of invasive pneumococcal disease (IPD) in children, certain key serotypes continue to cause serious illness that can lead to death in children under the age of 5, with serotypes 3, 22F, and 33F responsible for more than 25% of all IPD cases in this population," commented Dr. Steven Shapiro, chairman, department of pediatrics, Jefferson Abington Hospital, and investigator for the PNEU-PED trial, in a related press release issued on June 22, 2022.

"With the robust clinical data supporting VAXNEUVANCE and this FDA approval, VAXNEUVANCE will be an important new option to help advance protection for children."

IPD is an infection caused by the bacterium Streptococcus pneumoniae or pneumococcus. While there are approximately 100 different types of S. pneumoniae, called serotypes, a smaller number of serotypes are responsible for IPD in children.

Children under the age of 2 are particularly vulnerable to IPD.

The FDA initially approved VAXNEUVANCE in July 2021.

The FDA previously granted VAXNEUVANCE Breakthrough Therapy designation and Priority Review for the pediatric indication.

Note: This Merck media statement was manually curated for mobile readership.

Jun 22, 2022 • 8:33 am CDT

The UK Heath Security Agency (UKHSA) announced today it had found poliovirus in sewage samples collected from the London Beckton Sewage Treatment Works. However, the virus has only been detected in sewage samples.

Investigations are underway after several closely-related viruses were found in sewage samples taken between February and May 2022.

The virus is now classified as a 'vaccine-derived' poliovirus type 2 (VDPV2), which on rare occasions, can cause serious illness in people who are not fully vaccinated.

The detection of a VDPV2 suggests there has been some spread between closely-linked individuals in North and East London and that they are now shedding the type 2 poliovirus strain in their feces.

The UKHSA stated on June 22, 2022, 'As part of routine surveillance, it is normal for 1 to 3 'vaccine-like' polioviruses to be detected each year in U.K. sewage samples, but these have always been one-off findings that were not detected again.'

'These previous detections occurred when an individual vaccinated overseas with the live oral polio vaccine returned or traveled to the U.K. and briefly 'shed' traces of the vaccine-like poliovirus in their feces.

Jane Clegg, Chief nurse for the NHS in London, stated in a related media statement, 'The majority of Londoners are fully protected against Polio and won't need to take any further action, but the NHS will begin reaching out to parents of children aged under 5 in London who are not up to date with their Polio vaccinations to invite them to get protected.'

The last case of wild polio contracted in the U.K. was confirmed in 1984. And the U.K. was declared polio-free in 2003.

The Global Polio Eradication Initiative (GPEI) reported new cases as of June 15, 2022. In addition to outbreaks, polio is endemic in Afghanistan and Pakistan.

'Until poliovirus transmission is interrupted in these countries, all countries remain at risk of polio importation,' says the GPEI.

For example, Israel's Health Ministry confirmed in April 2022 that its ongoing polio vaccination campaign would expand beyond Jerusalem and be offered to about 2.5 million children.

In the USA, the U.S. CDC recommends that children get vaccinated to protect against poliomyelitis. Since 2000, an inactivated polio vaccine has been offered to children.

The CDC updated the pediatric and adult polio vaccination schedules on February 17, 2022.

Additional polio vaccine breaking news is posted at

Note: The UKHSA announcement was manually curated for mobile readership.

Jun 21, 2022 • 10:51 am CDT
from Pixabay

Maryland-based Emergent BioSolutions Inc. announced today that two-year persistence data evaluating the safety and immunogenicity of the company's investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate PXVX0317 were published in The Lancet Infectious Diseases.

The results from its phase 2 clinical study were published on June 13, 2022, and concluded a single 40 μg injection of adjuvanted PXVX0317 was well tolerated and induced a robust and durable serum neutralizing antibody immune response against CHIKV for up to 2 years.

"Emergent is pleased that results from our CHIKV VLP phase 2 study have been published and shared with the scientific community in The Lancet Infectious Diseases, a highly esteemed peer-reviewed journal," said Chris Cabell, M.D., chief medical officer and SVP clinical development at Emergent BioSolutions in a press release issued on June 21, 2022.

"Publication of this body of work highlights the importance of developing ways to address Chikungunya disease, a public health threat for which no vaccine or treatment exists."

This randomized, double-blind, parallel-group, phase 2 study was conducted at three U.S. sites with 415 CHIKV-naïve adults aged 18–45 years.

The primary endpoint was the geometric mean titer of the anti-CHIKV neutralizing antibody on day 57 (28 days after the last vaccination). Safety was also assessed.

As of June 21, 2022, the U.S. FDA has not approved a Chikungunya vaccine.

Additional chikungunya vaccine development news is posted at Vax-Before-Travel.

Note: Emergent's announcement was manually curated for mobile readers.

Jun 21, 2022 • 7:32 am CDT
by Barbara Jackson

New Jersey-based Merck announced today the presentation of positive results from the Phase 1/2 study, V116-001, evaluating the safety, tolerability, and immunogenicity of V116, the company's investigational 21-valent pneumococcal conjugate vaccine (PCV).

On June 21, 2022, Merck stated in pneumococcal vaccine-naïve adults 18-49 years of age (Phase 1) and 50 years of age and older (Phase 2), V116 met the primary immunogenicity objectives and was well-tolerated with an overall safety profile generally comparable to PNEUMOVAX®23 across age groups.

In the Phase 2 part of the study, V116 demonstrated non-inferior immune responses to PNEUMOVAX 23 for all shared serotypes and superior immune responses for the serotypes included in V116 but not included in PNEUMOVAX 23, based on study-defined criteria.

"Our encouraging data at ISPPD reflect the potential of V116 and Merck's tailored approach to developing pneumococcal vaccines to meet the specific needs of different populations," said Dr. Eliav Barr, SVP, head of global clinical development and chief medical officer, Merck Research Laboratories, in a related press release.

"Consistent with our portfolio strategy, V116 is designed to specifically target serotypes responsible for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the USA."

"Importantly, the eight serotypes in V116 that are not included in any currently-licensed pneumococcal vaccine account for over 30% of this disease burden alone."

Earlier this year, V116 received Breakthrough Therapy Designation from the U.S. FDA for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B.

Pneumococcal disease is an infection caused by the bacterium Streptococcus pneumoniae or pneumococcus.

Invasive forms of the pneumococcal disease can cause serious and potentially life-threatening infections such as bacteremia and meningitis.

Pneumonia (infection in the lungs), with or without bacteremia, also can occur.

Additional pneumococcal vaccine news is posted at PrecisionVaccinations.

Note: This Merck announcement was manually curated for mobile readers.

Jun 21, 2022 • 5:05 am CDT
by Hebi B.

A non-peer-reviewed computerized modeling study recently published by researchers at the London School of Hygiene & Tropical Medicine (LSHTM) suggests the monkeypox virus (MPXV) outbreak will continue expanding if it isn't curtailed soon.

Published online on June 13, 2022, LSHTM's U.K.-based case data indicates a possible MPXV reproduction growth rate exceeding (1).

'All scenarios projected that, without interventions or changes to behavior, a major outbreak is highly likely given the current outbreak size.'

However, 'the R0 may sharply decrease if control efforts are effective.'

As of June 21, 2022, the London area leads all other cities with over 550 MPXV patients.

Globally, about 2,780 patients have been reported in over fifty-six countries.

The World Health Organization and most other health agencies have begun offering preventive vaccines to MPXV patients' close contacts.

For example, Toronto Public Health continues to host monkeypox vaccination clinics for at-risk populations.

The two-dose MVA-BN (JYNNEOS®, USA, MVANEX®, Europe; IMVAMUNE®, Canada) was approved by the U.S. FDA in 2019.

On June 17, 2022, Dr. William Welfare, Incident Director at the U.K. Health Security Agency stated in a press release, 'As case numbers of monkeypox continue to rise and with many summer events and festivals ahead, we're reminding people to be aware of the symptoms to help prevent further spread and protect others.'

'If you have a rash with blisters, or any other monkeypox symptoms, don't go to events, meet with friends or have sexual contact.'

'Instead, stay at home .... and avoid close contact with others until a clinician has seen you.'

Additional monkeypox outbreak news is posted at Vax-Before-Travel.

Note: This information was manually curated for mobile readership.

Jun 21, 2022 • 4:24 am CDT
by Tumisu

The Taiwan Food and Drug Administration (FDA) recently granted emergency use authorization for the Novavax COVID-19 vaccine for adults. Local media reported Taiwan FDA experts agreed to approve Novavax's Nuvaxovid™, the first protein-based vaccine per Taiwan's pharmaceutical laws, on June 17, 2022.

Taiwan's Minister of Health and Welfare Chen Shih-chung confirmed in April 2022 that Taiwan would receive about 2 million Nuvaxovid vaccines through the global vaccine sharing initiative COVAX.

Additionally, the Australian Therapeutic Goods Administration (TGA) granted provisional registration of Nuvaxovid as a booster in individuals aged 18 and over on June 13, 2022.

The TGA granted provisional registration in January 2022 for use of Nuvaxovid for adults.

On June 7, 2022, the U.S. FDA's Vaccine Committee voted to endorse Novavax's COVID19 vaccine authorization. 

As of June 21, 2022, the U.S. FDA continues reviewing Novavax's authorization request.

Novavax Inc.'s vaccine candidates are genetically engineered using three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. 

This protein-based COVID-19 vaccine was designed in Gaithersburg, Maryland, is WHO authorized, and has been distributed in over 100 countries.

Note: This news was manually curated for mobile readership.

Jun 20, 2022 • 9:59 pm CDT

The U.S. Agency for International Development (USAID), in collaboration with COVAX, announced today they delivered the first two U.S.-facilitated shipments of Pfizer’s Comirnaty COVID-19 vaccines for children in Mongolia (302,400 doses) and Nepal (2.2 million doses).

During the second Global COVID-19 Summit in May 2022, the U.S. announced our commitment to expand COVID-19-related donations to include boosters and pediatric doses to meet partner countries’ demand for vaccines to immunize 5 to 11-year-olds.

In collaboration with COVAX, USAID stated on June 20, 2022, that it would continue to ship pediatric doses to partner countries worldwide that have requested them.

Given the availability of global COVID-19 vaccine supply, USAID is working with interested partner countries to expand vaccination to other groups, including children.

The U.S. FDA recently expanded Pfizer’s Comirnaty COVID-19 vaccine authorization to include 6-month-old infants in the USA.

Note: This USAID announcement was manually curated for mobile readers.

Jun 20, 2022 • 8:38 am CDT
by Niek Verlaan

France-based Valneva SE and Pfizer Inc. today announced that they have entered into new agreements for the Lyme disease vaccine candidate VLA15. As part of the Equity Subscription Agreement, Pfizer will invest €90.5 ($95) million in Valneva, which is planning to use the proceeds to support its Phase 3 development contribution to the Lyme disease program.

In addition, Valneva and Pfizer updated the terms of their VLA15 collaboration and license agreement which they announced on April 30, 2020.

As announced on April 26, 2022, Pfizer plans to initiate the Phase 3 study of VLA15 in the third quarter of 2022.

Pending successful initiation and completion of the planned Phase 3 study for VLA15, Pfizer could potentially submit a Biologics License Application to the U.S. FDA as early as 2025.

As of June 20, 2022, VLA15 is the only Lyme disease vaccine candidate in clinical development.

Valneva and Pfizer entered an initial collaboration agreement to co-develop VLA15 in April 2020.

 "Lyme disease continues to place a heavy burden on countries in North America and Europe, with an estimated 600,000 cases each year across both regions," said Kathrin U. Jansen, Ph.D., SVP and Head of Vaccine Research & Development at Pfizer, in a press release issued on June 20, 2022.

"As the geographic footprint of Lyme disease widens, the medical need for vaccination becomes even more imperative."

"We are excited to continue partnering with Valneva on the development of VLA15 and look forward to working together to progress the program to bring forward a vaccine that could help prevent this debilitating disease."

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease.

OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Lyme disease is a systemic infection caused by Borrelia burgdorferi bacteria transmitted to humans by infected Ixodes ticks.

It is considered the most common vector-borne illness in the Northern Hemisphere.

According to a study published on June 13, 2022, in BMJ Global Health, Lyme disease has likely infected 14.5% of the world's population.

Note: This Valneva announcement was manually curated for mobile readership.

Jun 19, 2022 • 7:38 am CDT

The European Medicines Agency (EMA) recently announced it started a rolling review for a bivalent version of Moderna Inc.'s Spikevax vaccine adapted to protect against specific variants of the SARS-CoV-2 coronavirus.

Announced on June 17, 2022, the EMA confirmed this mRNA vaccine candidate would target two strains of SARS-CoV-2, in this case, the original strain and the newer Omicron variant of concern.

Currently, Omicron's BA.4 and BA.5 variants are dominating throughout Europe.

By starting this rolling review for Spikevax, EMA's human medicines committee (CHMP) will be able to review data from ongoing studies as they become available. 

The EMA review will continue until there is enough data for a formal application.

The composition of adapted COVID-19 vaccines will ultimately depend on the recommendations of public health authorities and the World Health Organization.

As of May 15, 2022, about 152 million doses of Spikevax had been given to people in the EU/EEA.

The EMA recently confirmed a total of 219,135 cases of suspected spontaneous side effects were reported from EU/EEA countries, with 1,059 of these reporting a fatal outcome.

Note: This EMA announcement was manually curated for mobile readership.

Jun 19, 2022 • 4:04 am CDT
GH map

Toronto Public Health hosted two vaccine clinics yesterday for those most at-risk of contracting the monkeypox virus (MPXV). Toronto's health unit said the clinics are intended for adults who self-identify as male and have sex with other men.

Canada's government has approved the IMVANEX® (Jynneos, MVA-BN) vaccine for use in 2022.

"We're trying to avoid the stigmatization of gay men," Rita Shahin, Toronto's associate medical officer of health, told CBC News on June 18, 2022.

The Public Health Agency of Canada confirmed 168 monkeypox cases in Canada as of June 17, 2022.

The MPXV patients breakdown by province is Quebec (141), Ontario (21), British Columbia (4), and Alberta (2).

Furthermore, Canada advises a 21-day, multi-step quarantine plan for MPXV patients and close contacts.

Globally, there are now 2,662 potential cases.

And in the USA, twenty states had reported (113) MPXV patients as of June 17, 2022. Of the confirmed cases, California, Illinois, and New York City have reported (60) since May 2022.

Additional monkeypox outbreak news is posted at Vax-Before-Travel.

Note: This information was curated for mobile readers.

Jun 19, 2022 • 3:23 am CDT

The U.S. C.D.C. Director Rochelle P. Walensky, M.D., M.P.H., announced her endorsement of the Advisory Committee on Immunization Practices' recommendation that all children six months through 5 years of age should receive an mRNA COVID-19 vaccine.

This confirmation expands COVID-19 vaccination eligibility to nearly 20 million additional children in the U.S.A.

All children, including children who have already had COVID-19, should get vaccinated.

Dr. Walensky stated on June 18, 2022, "Together, with science leading the charge, we have taken another important step forward in our nation's fight against COVID-19."

"We know millions of parents and caregivers are eager to get their young children vaccinated, and with today's decision, they can."

"I encourage parents and caregivers with questions to talk to their doctor, nurse, or local pharmacist to learn more about the benefits of vaccinations and the importance of protecting their children by getting vaccinated."    

Parents and caregivers can play an active role in monitoring the safety of these vaccines by signing their children up for v-safe – personalized and confidential health check-ins via text messages and web surveys where they can easily share with C.D.C. how a child feels after getting a COVID-19 vaccine, says the C.D.C.

The distribution of pediatric vaccinations for these younger children has started across the country.

This week, it will be available at thousands of pediatric practices, pharmacies, Federally Qualified Health Centers, local health departments, clinics, and other locations.

Children in this younger age group can be vaccinated with whichever mRNA vaccine is available (Moderna or Pfizer-BioNTech).

Visit to see where vaccines for children are available.

The C.D.C. reported on June 17, 2022, that about 66.8% of the U.S. population had been 'fully vaccinated' with an Approve/Authorized COVID-19 vaccine.

And about 47.2% of eligible people have been 'boosted' and are now 'up to date' vaccinated.

Note: This announcement was manually curated for mobile readership.

Jun 19, 2022 • 2:57 am CDT

The U.S. CDC published its last Weekly U.S. Influenza Surveillance Report for the 2021-2022 flu season on June 17, 2022. Due to late-season activity, FluSurv-NET surveillance was extended beyond the typical end date of April 30.

The first full report for the 2022-23 flu season will be published on October 14, 2022.

For Week #23, the CDC's report stated:

  • Seasonal influenza activity is decreasing nationally.

  • One influenza-associated pediatric death was reported this week. Therefore, a total of (29) influenza-associated pediatric deaths occurring this season have been reported.

  • The majority of influenza viruses detected are A(H3N2). H3N2 viruses identified this season are genetically closely related to the vaccine virus. Antigenic data show that most of the H3N2 viruses characterized are antigenically different from the vaccine reference viruses. While the number of B/Victoria viruses circulating this season is small, most of the B/Victoria viruses characterized are antigenically similar to the vaccine reference virus.

  • The percentage of outpatient visits due to respiratory illness has decreased compared to last week and has trended downward over the past four weeks. Influenza contributes to respiratory illness levels, but other respiratory viruses are also circulating. Therefore, the relative contribution of influenza varies by location.

  • The number of hospital admissions with laboratory-confirmed influenza reported to HHS Protect decreased compared to last week and has been trending downward since late April.

The CDC reaffirmed 'An annual flu vaccine is the best way to protect against flu.'

'Vaccination can prevent serious outcomes in people who get vaccinated but still get sick.'

And the CDC 'continues to recommend that everyone ages six months and older get a flu vaccine as long as flu activity continues.'

News regarding the Southern Hemisphere flu season will be reported at

Note: The CDC report was manually curated for mobile readers.